Publications by authors named "Jan-Maarten van Woerkom"
This study aims to determine whether patients with rheumatoid arthritis (RA) experience more general feelings of guilt and shame than their peers without RA and to examine possible correlates of guilt and shame in RA. In a cross-sectional survey study, 85 out-patients with RA (77 % female; median disease duration, 11 years) and 59 peer controls completed the Experience of Shame Scale (ESS) and the Test of Self-Conscious Affect (TOSCA). Patients additionally completed measures of health status, self-efficacy, cognitive emotion regulation, and numerical rating scales for life satisfaction and happiness.
View Article and Find Full Text PDFIntroduction: The aim of this study was to determine the prevalence of gastrointestinal and behavioural symptoms occurring before (anticipatory/associative) and after methotrexate (MTX) administration, termed MTX intolerance, in rheumatoid (RA) and psoriatic arthritis (PsA).
Methods: Methotrexate Intolerance Severity Score (MISS), previously validated in juvenile idiopathic arthritis patients, was used to determine MTX intolerance prevalence in 291 RA/PsA patients. The MISS consisted of four domains: abdominal pain, nausea, vomiting and behavioural symptoms, occurring upon, prior to (anticipatory) and when thinking of MTX (associative).
Article Synopsis
- This study aimed to explore the relationship between the effects of leflunomide on the immune system and its clinical effectiveness in treating primary Sjögren's syndrome (SS).
- After 24 weeks of leflunomide treatment, there was a notable reduction in inflammatory cytokines like IL-1β and TNFα in patients, particularly among those who responded positively to the treatment.
- The findings indicate that leflunomide may improve clinical outcomes in primary SS by selectively targeting T-cell responses, suggesting a potential strategy for enhancing treatment efficacy and safety.